PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control liber.

## UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No. PH-7263 First Inventor or Application Identifier

John M. Fevig et al

Substituted Pyrroloquinolines and Pyridoquinolines as Title Serotonin Agonists and Antagonists

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Express Mail Label No.

EV000875525US

	APP	PLICATION ELEME	ENTS	T.,	ADDRESS TO  Assistant Commissioner for Patents Box Patent Application					
	EP chapter 600 con	nceming utility patent applica	cation contents.			O Box Paten Washingto	nt Application on, DC 20231			
1. \( \times \) 2. \( \times \) 3. \( \times \)	Fee Transmitta (Submit an origin Applicant claim See 37 CFR 1. Specification (preferred arrang - Descriptive title - Cross Referenc - Statement Rega - Reference to se program listing - Background of t - Brief Summary	tal Form (e.g., PTO/SB/1 and and a duplicate for fee p ms small entity status.  2.27.  [Total Pagement set forth below)  e of the Invention ces to Related Applications arding Fed sponsored R & Eequence listing, a table, or a pappendix the Invention of the Invention on of the Drawings ( if filed) iption	17) processing) Pages 323 ]	7.	Washington, DC 20231  7.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a.  Computer Readable Form (CRF)  b. Specification Sequence Listing on:     i.  CD-ROM or CD-R (2 copies); or     ii.  paper  c.  Statements verifying identity of above copies  ACCOMPANYING APPLICATIONS PARTS  9.  Assignment Papers (cover sheet & document(s))  10.  37 C.F.R.§3.73(b)Statement Power of (when there is an assignee)  Attorney					
a. [ b. [ i 6. ⊠ A	Drawing(s) (35 ath or Declaration  Newly execut  Copy from a property of a continu  DELETION Signed statem named in the property 1.63(d)(2) and Application Data Statements	U.S.C.113) [Total Solution [Total Form Total Form Total Form Ited (original or copy) prior application (37 CFF Lation/divisional with Box NOF INVENTOR(S) lent attached deleting invent prior application, see 37 CFI 1.33(b).  Sheet. See 37 CFR 1.76	Pages 2  R 1.63 (d))  x 17 completed)  ntor(s)  R	11.	12.  Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  13.  Preliminary Amendment  14.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15.  Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Other:					
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) Of prior application No: Group Art Unit:  For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  17. CORRESPONDENCE ADDRESS										
*24348* or □ Correspondence address below  24348  PATENT TRADEMARK OFFICE										
Name	Scott K. Larse	Scott K. Larsen								
Address		Bristol-Myers Squibb Pharma Company P.O. Box 4000								
City	Princeton		State N	New Jersey	у	Zip Code	08543-4000			
Country	U.S.A.	Te		(302) 695-1		Fax	(302) 695-8399			
Name (F	Print/Type)	Scott K. Larsen, Ph.D.	., J.D. <i>Re</i>	egistration	egistration No. (Attorney/		38,532			
Signature		Parci		2		Date	December 19, 2001			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

. 4  Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision. **EXPRESS MAIL NO.: 000875525 US** 

MAILED: December 19, 2001

\*\*or number previously paid, if greater; For Reissues, see above

Complete if Known

Application Number Unknown

Filing Date December 19, 2001

First Named Inventor John M. Fevig et al

Examiner Name Unknown

Group / Art Unit Unknown

Attorney Docket No. PH-7263

884.00 TOTAL AMOUNT OF PAYMENT (\$) Attorney Docket No. METHOD OF PAYMENT (check one) FEE CALCULATION (continued) The Commissioner is hereby authorized to charge 3. ADDITIONAL FEES  $\boxtimes$ 1. indicated fees and credit any over payments to: Small Entity rge Fee Description Deposit Code (\$) Code (\$) Paid  $\boxtimes$ 023850 105 130 205 65 Surcharge - late filing fee or oath Number 127 50 227 25 Surcharge - late provisional filing fee or cover sheet. Deposit **Bristol-Myers Squibb Pharma**  $\boxtimes$ 139 130 139 130 Non-English specification Account Company For filing a request for ex parte 147 2,520 147 2,520 Charge Any Additional Fee Required reexamination Under 37 CFR 1.16 and 1.17 112 920\* 112 920\* Requesting publication of SIR prior to Applicant claims small entity status. Examiner action See 37 CFR 1.27 113 1,840\* 113 Requesting publication of SIR after Payment Enclosed Examiner action 115 110 215 55 Extension for reply within first month ☐ Check □ Credit card ☐ Money ☐ Other 116 400 216 195 Extension for reply within second month **FEE CALCULATION** 117 920 217 445 Extension for reply within third month BASIC FILING FEE 118 1,440 218 695 Extension for reply within fourth **Entity Small** Entity 128 1,960 228 Extension for reply within fifth month 945 Fee Code Fee Fee Fee Description (\$) Code (\$) Fee Paid 119 310 219 155 Notice of Appeal 310 101 120 220 155 740 201 355 Utility filing fee 740 00 Filing a brief in support of an appeal ≅106 330 206 160 Design filing fee 121 270 221 135 Request for oral hearing 197 510 207 245 Plant filing fee Petition to institute a public use 138 1,510 138 1,510 proceeding 108 740 208 355 Reissue filing fee 140 110 240 55 Petition to revive - unavoidable 114 160 214 75 Provisional filling fee 141 1,240 241 620 Petition to revive - unintentional SUBTOTAL (1) (\$) 740 00 142 1,240 242 620 Utility issue fee (or reissue) 143 440 243 220 Design issue fee 2. EXTRA CLAIM FEES 144 600 244 300 Plant issue fee Extra Fee from 122 130 122 130 Petitions to the Commissioner Claims Paid Petitions related to provisional Total Claims -20\*\* 8 Х 18 144 123 130 123 50 applications Independent Claims -3\*\* 0 х 0 Submission of Information Disclosure 126 240 126 240 Stmt Multiple Dependent х 0 Recording each patent assignment Large Entity Small Entity 581 40 581 40 per property (times number of properties) Fee Fee Code Fee Description Code 146 710 246 355 Filing a submission after final rejection (\$) (\$) (37 CFR § 1.129(a)) 103 203 18 9 Claims in excess of 20 149 710 249 355 For each additional invention to be 102 84 202 40 Independent claims in excess of 3 examined (37 CFR § 1 129(b)) 280 104 204 Multiple dependent claim, if not paid 710 Reissue independent claims over 279 355 Request for Continued Examination 109 84 209 40 (RCE) original patent \*\* Reissue claims in excess of 20 and 169 900 169 Request for expedited examination 110 18 210 9 over original patent of a design application SUBTOTAL (2) (\$) 144.00 Other fee (specify) \*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

SUBMITTED BY Complete (if applicable)										
Name (Print/Type)	Scott K. Larsen	Registration No. Attorney/Agent)	38,532	Telephone	302-695-1406					
Signature	Mar	-1/2		Date	December 19, 2001					

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.